Opendata, web and dolomites

TheraLymph SIGNED

Gene Therapy to restore lymphatic flow lymphedema

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TheraLymph project word cloud

Explore the words cloud of the TheraLymph project. It provides you a very rough idea of what is the project "TheraLymph" about.

vegfc    substantially    accumulation    arm    western    clinical    endothelium    handicapping    hospital    deeper    cancer    vascular    theralymph    ten    lymphedematous    toulouse    perform    rangueil    lipids    painful    vectors    combination    generally    life    scientists    quality    multiple    decades    integrative    lentiviral    120    network    lymphangiogenic    pi    collectors    laboratory    percent    impacts    microenvironmental    modified    disappointing    disabling    possess    human    fifteen    intrinsic    fluid    treatments    breast    superficial    medical    therapy    preclinical    hosted    efficient    validate    translational    transient    disease    vivo    risk    bench    decipher    women    molecules    models    performed    unmet    diseases    countries    innovative    medicine    cardiovascular    peptides    effect    millions    physicians    dysfunction    located    untreatable    brings    leg    gene    trial    pathology    cartography    consequence    lentiflash    fat    restores    people    lymphedema    monotherapy    drainage    synergistic    lymphatic    molecule    worldwide   

Project "TheraLymph" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 8˙064˙946 €
 EC max contribution 8˙064˙946 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 1˙475˙531.00
2    FLASH THERAPEUTICS FR (TOULOUSE) participant 1˙132˙908.00
3    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) participant 1˙046˙198.00
4    CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE FR (TOULOUSE CEDEX 3) participant 947˙000.00
5    UNIVERSITE DE LAUSANNE CH (LAUSANNE) participant 868˙185.00
6    UNIVERSITE DE LIEGE BE (LIEGE) participant 706˙250.00
7    DE DUVE INSTITUTE BE (BRUXELLES) participant 608˙335.00
8    UPPSALA UNIVERSITET SE (UPPSALA) participant 455˙000.00
9    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 317˙287.00
10    UNIVERZITA KARLOVA CZ (PRAHA 1) participant 293˙750.00
11    INSERM - TRANSFERT SA FR (PARIS) participant 214˙500.00

Map

 Project objective

Lymphedema is a disabling condition induced by the accumulation of fluid and fat in the arm or in the leg. It is an untreatable disease that affects 4 millions people in Europe and more than 120 millions people worldwide. It is handicapping, painful and impacts substantially the quality of life. In western countries, lymphedema is generally a consequence of cancer treatments i.e. ten to fifteen percent of women will develop lymphedema after breast cancer. The main objective of Theralymph will be to establish a non-integrative gene therapy for this unmet medical need. The theralymph translational research program brings together bench scientists from 5 European countries and physicians from the hosted Rangueil hospital in which the PI institute is located to perform a Phase I/II trial focusing on women who developed lymphedema after breast cancer. Based on decades of disappointing results of monotherapy-gene delivery in cardiovascular diseases, our approach will be based on multiple gene therapy targeting both superficial lymphatic endothelium and deeper lymphatic collectors. We will identify molecules that possess a synergistic effect with the established lymphangiogenic factor VEGFC. Theralymph project will determine risk factors for lymphedema and cartography the lymphatic network in the pathology. It will decipher whether lymphatic intrinsic molecules or microenvironmental peptides or lipids are modified in the lymphedematous arm to promote the lymphatic dysfunction. Theralymph will validate the best molecule combination that restores the lymphatic drainage in in preclinical lymphedema models before human study. The Phase I/II gene therapy clinical trial will be performed in the vascular medicine department of Toulouse’s hospital, where the PI laboratory is located. This trial will use an innovative technology based on recently developed non-integrative lentiflash lentiviral vectors that allow a transient and highly efficient in vivo gene delivery.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERALYMPH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERALYMPH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

SBR (2020)

SMART BONE REGENERATION

Read More  

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More